The repurposing of ivermectin for malaria: a prospective pharmacokinetics-based virtual clinical trials assessment of dosing regimen options

Research output: Contribution to journalArticle

View graph of relations Save citation



Research units


Ivermectin has demonstrated many successes in the treatment of a range of nematode infections. Considering the increase in malaria resistance attention has turned towards ivermectin as a candidate for repurposing for malaria. This study developed and validated an ivermectin physiologically-based pharmacokinetic model in healthy adults (20-50 years) and paediatric (3-5 years/15-25 kg) subjects and in a representative adult malaria population group (Thailand). Dosing optimisation demonstrated a twice daily for 3- or 5-day regimens would provide a time above the LC50 of more than 7 days for adult and paediatric. Furthermore, to address the occurrence of CYP450-induction often encountered with antiretroviral agents, simulated drug-drug interaction studies with efavirenz highlighted that a 1 mg/kg once daily dose for five days would counteract the increased ivermectin hepatic clearance and enable a time above LC50 of 138.8 hours in adults and 141.2 hours in paediatric subjects. It was also demonstrated that dosage regimen design would require consideration of the age-weight geographical relationship of the subjects, with a dosage regimen for a representative Thailand population group requiring at least a single daily dose for 5 days to maintain ivermectin plasma concentrations and a time above LC50 similar to that in healthy adults.


  • The repurposing of ivermectin for malaria

    Rights statement: © 2018, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

    Accepted author manuscript, 2 MB, PDF-document

    Licence: CC BY-NC-ND Show licence


Original languageEnglish
JournalJournal of Pharmaceutical Sciences
Early online date5 Apr 2018
Publication statusE-pub ahead of print - 5 Apr 2018

Bibliographic note

© 2018, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International


  • Physiologically-based pharmacokinetics, pharmacokinetics, drug resistance, Onychomycosis, n-silico modelling

Employable Graduates; Exploitable Research

Copy the text from this field...